{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T06:46:19Z","timestamp":1792133179398,"version":"4.4.0"},"reference-count":40,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2022,10,31]],"date-time":"2022-10-31T00:00:00Z","timestamp":1667174400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Universidad C\u00e9sar Vallejo, Trujillo, Per\u00fa"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["TropicalMed"],"abstract":"<jats:p>Tuberculosis and diabetes mellitus are two global pandemics and rising public health problems. Recent studies suggest that oral antidiabetic drugs (OADs) could reduce the risk of tuberculosis and improve clinical outcomes. However, the evidence is controversial. Therefore, we aimed to assess the effect of OADs on the risk of tuberculosis and treatment outcomes. We systematically searched for six databases from inception to 31 August 2022. We followed a predefined PICO\/PECO strategy and included two randomized controlled trials and sixteen observational studies. This study collects 1,109,660 participants, 908,211 diabetic patients, and at least 13,841 tuberculosis cases. Our results show that metformin decreases the risk of active tuberculosis by 40% (RR 0.60; 95% CI 0.47\u20130.77) in diabetic patients. In addition, metformin exhibits a dose-response gradient (medium doses reduce the risk of active tuberculosis by 45%, while high doses reduce this risk by 52%). On the other hand, DPP IV inhibitors increase the risk of active tuberculosis by 43% (RR 1.43; 95% CI 1.02\u20132.02). Subgroup analysis showed that study design and metformin dose accounted for the heterogeneity. We conclude that metformin significantly protects against active tuberculosis among diabetic patients. On the contrary, DPP IV inhibitors could increase the risk of developing active tuberculosis.<\/jats:p>","DOI":"10.3390\/tropicalmed7110343","type":"journal-article","created":{"date-parts":[[2022,11,2]],"date-time":"2022-11-02T03:44:17Z","timestamp":1667360657000},"page":"343","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Effect of Oral Antidiabetic Drugs on Tuberculosis Risk and Treatment Outcomes: Systematic Review and Meta-Analysis"],"prefix":"10.3390","volume":"7","author":[{"given":"Edinson Dante","family":"Meregildo-Rodriguez","sequence":"first","affiliation":[{"name":"Escuela de Medicina, Universidad C\u00e9sar Vallejo, Trujillo 13001, Peru"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1814-5593","authenticated-orcid":false,"given":"Martha Genara","family":"Asmat-Rubio","sequence":"additional","affiliation":[{"name":"Escuela de Posgrado, Universidad Privada Antenor Orrego, Trujillo 13008, Peru"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petterson","family":"Zavaleta-Alaya","sequence":"additional","affiliation":[{"name":"Escuela de Posgrado, Universidad Privada Antenor Orrego, Trujillo 13008, Peru"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2109-6430","authenticated-orcid":false,"given":"Gustavo Adolfo","family":"V\u00e1squez-Tirado","sequence":"additional","affiliation":[{"name":"Escuela de Medicina, Universidad Privada Antenor Orrego, Trujillo 13008, Peru"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,10,31]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Restrepo, B.I. (2016). Diabetes and tuberculosis. Microbiol. Spectr., 4.","DOI":"10.1128\/microbiolspec.TNMI7-0023-2016"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/imm.12762","article-title":"Influence of diabetes mellitus on immunity to human tuberculosis","volume":"152","author":"Nathella","year":"2017","journal-title":"Immunology"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1002\/eji.201344301","article-title":"Diabetes and immunity to tuberculosis","volume":"44","author":"Martinez","year":"2014","journal-title":"Eur. J. Immunol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"783","DOI":"10.5588\/ijtld.18.0433","article-title":"The effects of diabetes on tuberculosis treatment outcomes: An updated systematic review and meta-analysis","volume":"23","author":"Huangfu","year":"2019","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Yu, X., Li, L., Xia, L., Feng, X., Chen, F., Cao, S., and Wei, X. (2019). Impact of metformin on the risk and treatment outcomes of tuberculosis in diabetics: A systematic review. BMC Infect. Dis., 19.","DOI":"10.1186\/s12879-019-4548-4"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s00228-019-02786-y","article-title":"Impacts of metformin on tuberculosis incidence and clinical outcomes in patients with diabetes: A systematic review and meta-analysis","volume":"76","author":"Zhang","year":"2020","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1093\/cid\/ciab964","article-title":"Randomized Trial of Metformin with Anti-Tuberculosis Drugs for Early Sputum Conversion in Adults with Pulmonary Tuberculosis","volume":"75","author":"Padmapriydarsini","year":"2022","journal-title":"Clin. Infect. Dis."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Heo, E., Kim, E., Jang, E.J., and Lee, C.H. (2021). The cumulative dose-dependent effects of metformin on the development of tuberculosis in patients newly diagnosed with type 2 diabetes mellitus. BMC Pulm. Med., 21.","DOI":"10.1186\/s12890-021-01667-4"},{"key":"ref_9","unstructured":"Higgins, J., and Green, S. (2022, September 07). Cochrane Handbook for Systematic Reviews of Interventions. Available online: https:\/\/handbook-5-1.cochrane.org\/."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Moher, D., Liberati, A., Tetzlaff, J., Altman, D.G., and The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med., 6.","DOI":"10.1371\/journal.pmed.1000097"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Shea, B.J., Reeves, B.C., Wells, G., Thuku, M., Hamel, C., Moran, J., Moher, D., Tugwell, P., Welch, V., and Kristjansson, E. (2017). AMSTAR 2: A critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ, 358.","DOI":"10.1136\/bmj.j4008"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e13249","DOI":"10.1111\/eci.13249","article-title":"Relative risks and odds ratios: Simple rules on when and how to use them","volume":"50","author":"McKenzie","year":"2020","journal-title":"Eur. J. Clin. Investig."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1002\/jrsm.46","article-title":"Pooling health-related quality of life outcomes in meta-analysis-a tutorial and review of methods for enhancing interpretability","volume":"2","author":"Thorlund","year":"2011","journal-title":"Res. Synth. Methods"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2967","DOI":"10.1002\/sim.4298","article-title":"Expressing findings from meta-analyses of continuous outcomes in terms of risks","volume":"30","author":"Sarpatwari","year":"2011","journal-title":"Stat Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"933","DOI":"10.3904\/kjim.2017.249","article-title":"The effect of metformin on culture conversion in tuberculosis patients with diabetes mellitus","volume":"33","author":"Lee","year":"2018","journal-title":"Korean J. Intern. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1093\/cid\/cix819","article-title":"Metformin Use Reverses the Increased Mortality Associated with Diabetes Mellitus During Tuberculosis Treatment","volume":"66","author":"Degner","year":"2018","journal-title":"Clin. Infect. Dis."},{"key":"ref_17","first-page":"22","article-title":"Anti-Diabetic Medication Reduces Risk of Pulmonary Tuberculosis in Diabetic Patients: A Population-based Cohort Study in Taiwan","volume":"49","author":"Lin","year":"2017","journal-title":"Kuwait Med. J."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1111\/resp.13338","article-title":"Metformin is associated with a lower risk of active tuberculosis in patients with type 2 diabetes: Metformin reduces TB risk in diabetics","volume":"23","author":"Lin","year":"2018","journal-title":"Respirology"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"8085106","DOI":"10.1155\/2020\/8085106","article-title":"\u03b1-Glucosidase Inhibitor Can Effectively Inhibit the Risk of Tuberculosis in Patients with Diabetes: A Nested Case-Control Study","volume":"2020","author":"Lin","year":"2020","journal-title":"BioMed Res. Int."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Lee, M.C., Chiang, C.Y., Lee, C.H., Ho, C.M., Chang, C.H., Wang, J.Y., and Chen, S.M. (2018). Metformin use is associated with a low risk of tuberculosis among newly diagnosed diabetes mellitus patients with normal renal function: A nationwide cohort study with validated diagnostic criteria. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0205807"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Lee, M.C., Lee, C.H., Lee, M.R., Wang, J.Y., and Chen, S.M. (2019). Impact of metformin use among tuberculosis close contacts with diabetes mellitus in a nationwide cohort study. BMC Infect. Dis., 19.","DOI":"10.1186\/s12879-019-4577-z"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/j.chest.2017.11.040","article-title":"The Risk of TB in Patients with Type 2 Diabetes Initiating Metformin vs. Sulfonylurea Treatment","volume":"153","author":"Pan","year":"2018","journal-title":"Chest"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Tseng, C.H. (2018). Metformin Decreases Risk of Tuberculosis Infection in Type 2 Diabetes Patients. J. Clin. Med., 7.","DOI":"10.3390\/jcm7090264"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Al-Shaer, M.H., Elewa, H., Alkabab, Y., Nazer, L.H., and Heysell, S.K. (2018). Fixed-dose combination associated with faster time to smear conversion compared to separate tablets of anti-tuberculosis drugs in patients with poorly controlled diabetes and pulmonary tuberculosis in Qatar. BMC Infect. Dis., 18.","DOI":"10.1186\/s12879-018-3309-0"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"924","DOI":"10.5588\/ijtld.18.0687","article-title":"Metformin and tuberculosis risk in elderly patients with diabetes mellitus","volume":"23","author":"Park","year":"2019","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1111\/jdi.13523","article-title":"Metformin as a potential protective therapy against tuberculosis in patients with diabetes mellitus: A retrospective cohort study in a single teaching hospital","volume":"12","author":"Fu","year":"2021","journal-title":"J. Diabetes Investig."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.21037\/apm-20-278","article-title":"Effects of dipeptidyl peptidase-4 inhibitor treatment doses on tuberculosis in patients with diabetes: A long-term nationwide population-based cohort study","volume":"9","author":"Chen","year":"2020","journal-title":"Ann. Palliat. Med."},{"key":"ref_28","unstructured":"US Food and Drug Administration (2022, September 08). Highlights of Prescribing Information. Kombiglyze\u00ae XR (Saxagliptin and Metformin Hydrochloride Extended-Release), Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/200678s024lbl.pdf."},{"key":"ref_29","first-page":"A4313","article-title":"The Effect of Metformin Versus Sulfonylurea on the Risk of Tuberculosis Disease in Patients with Type 2 Diabetes Mellitus: A Population-Based Cohort Study","volume":"197","author":"Su","year":"2018","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1111\/j.1463-1326.2012.01659.x","article-title":"Dapagliflozin monotherapy in drug-na\u00efve patients with diabetes: A randomized-controlled trial of low-dose range","volume":"14","author":"Bailey","year":"2012","journal-title":"Diabetes Obes. Metab."},{"key":"ref_31","unstructured":"WHO Collaborating Centre for Drug Statistics Methodology (2022, September 09). Definition and General Considerations. Available online: https:\/\/www.whocc.no\/ddd\/definition_and_general_considera\/."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"828939","DOI":"10.1155\/2013\/828939","article-title":"Risk Factors for Tuberculosis","volume":"2013","author":"Narasimhan","year":"2013","journal-title":"Pulm. Med."},{"key":"ref_33","first-page":"194","article-title":"Further insights into to the role of statins against active tuberculosis: Systematic review and meta-analysis","volume":"30","year":"2022","journal-title":"Infez. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.ijid.2020.01.036","article-title":"Statin use and risk of tuberculosis: A systemic review of observational studies","volume":"93","author":"Duan","year":"2020","journal-title":"Int. J. Infect. Dis."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"121","DOI":"10.3389\/fmed.2020.00121","article-title":"Statin Use May Be Associated with Reduced Active Tuberculosis Infection: A Meta-Analysis of Observational Studies","volume":"7","author":"Li","year":"2020","journal-title":"Front. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.ajog.2008.12.020","article-title":"Meta-Analysis versus Large Clinical Trials: Which Should Guide Our Management?","volume":"200","author":"Scifres","year":"2009","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.cmi.2020.11.006","article-title":"Reporting of systematic reviews and meta-analysis of observational studies","volume":"27","author":"Paul","year":"2021","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Liu, T., Nie, X., Wu, Z., Zhang, Y., Feng, G., Cai, S., Lv, Y., and Peng, X. (2017). Can statistic adjustment of OR minimize the potential confounding bias for meta-analysis of case-control study? A secondary data analysis. BMC Med. Res. Methodol., 17.","DOI":"10.1186\/s12874-017-0454-x"},{"key":"ref_39","unstructured":"(2013). Saxagliptin and tuberculosis. Prescrire Int., 22, 17."},{"key":"ref_40","unstructured":"(2011). Saxagliptin. No more effective than other gliptins, but a high potential for drug interactions. Prescrire Int., 20, 33\u201337."}],"container-title":["Tropical Medicine and Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2414-6366\/7\/11\/343\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:06:59Z","timestamp":1760144819000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2414-6366\/7\/11\/343"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,31]]},"references-count":40,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2022,11]]}},"alternative-id":["tropicalmed7110343"],"URL":"https:\/\/doi.org\/10.3390\/tropicalmed7110343","relation":{},"ISSN":["2414-6366"],"issn-type":[{"value":"2414-6366","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,31]]}}}